好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Early Detection of Persons at Risk for Incident CM
Headache
P3 - Poster Session 3 (5:30 PM-6:30 PM)
13-025

To improve the early detection of persons with headache at increased risk for incident chronic migraine (CM).

Detection of persons with headache at risk for developing CM is essential to the development of preventive interventions.  Latent transition models provide a promising approach for identifying groups at high risk for CM (Collins & Lanza, 2009; Ip, 2013).

Using longitudinal data from the 2005 and 2007 American Migraine Prevalence and Prevention Study surveys, we fit latent transition models to identify natural subgroups of people with headache. Headache-related domains upon which transitions were modeled included migraine-defining symptoms, allodynia (Allodynia Symptom Checklist, ASC-12) and headache frequency plus disability (Migraine Disability Assessment Scale). The model assigned subjects to transition classes, reflecting changes in these domains occurring between 2005 and 2007.  Models were estimated in R version 3.5.1.  We assessed the incidence of CM in 2009 for each latent transition class.

In the 3948 subjects contributing data in 2005, 2007, and 2009, 404 (10%) populated the estimated transition classes believed to be at risk for disease progression. The 2009 incident CM rate among subjects in these classes – 16.1% - was greater than the total-sample 2009 incident CM rate of 2.6%.

Latent transition classes predicted the onset of CM in persons with headache. The 2-year early detection CM incidence rate was greater than the previously reported annual rate and cumulative quarterly rate within a year. This suggests that more subjects may be at risk for incident CM than is currently expected, and that these subjects can be detected. Additional validation should be done on an independent sample to confirm that particular latent transition classes can indeed predict incident migraine.

Authors/Disclosures
Charles Iaconangelo, PhD (Pharmerit)
PRESENTER
Dr. Iaconangelo has received personal compensation for serving as an employee of Open Health Group.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
No disclosure on file